Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

Thorax
Leona BessonovaDiana Bilton

Abstract

Ivacaftor is the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator demonstrating clinical benefit in patients with cystic fibrosis (CF). As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare providers. This ongoing, observational, postapproval safety study evaluates clinical outcomes and disease progression in ivacaftor-treated patients using data from the US and the UK CF registries following commercial availability. Annual analyses compare ivacaftor-treated and untreated matched comparator patients for: risks of death, transplantation, hospitalisation, pulmonary exacerbation; prevalence of CF-related complications and microorganisms and lung function changes in a subset of patients who initiated ivacaftor in the first year of commercial availability. Results from the 2014 analyses (2 and 3 years following commercial availability in the UK and USA, respectively) are presented here. Analyses included 1256 ivacaftor-treated and 6200 comparator patients from the USA and 411 ivacaftor-treated and 2069 comparator patients from the UK. No new safety concerns were identified based on the evaluation of clinical outcomes included in the anal...Continue Reading

References

Nov 5, 1997·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·P T Sawicki
Feb 24, 2001·American Journal of Epidemiology·T G LiouB C Marshall
Feb 27, 2007·Diabetes Care·Sarah Jane SchwarzenbergAntoinette Moran
May 14, 2010·American Journal of Respiratory and Critical Care Medicine·Don B SandersChristopher H Goss
Nov 4, 2011·The New England Journal of Medicine·Bonnie W RamseyUNKNOWN VX08-770-102 Study Group
Apr 18, 2013·American Journal of Respiratory and Critical Care Medicine·Jane C DaviesUNKNOWN VX08-770-103 (ENVISION) Study Group
May 6, 2014·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·A H Gifford
Jun 14, 2014·American Journal of Respiratory and Critical Care Medicine·Steven M RoweUNKNOWN GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network
Jul 23, 2014·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Shahid I SheikhDon Hayes
Oct 1, 2014·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Kris De BoeckMark Higgins
Nov 27, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sonya L HeltsheUNKNOWN GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network
Jun 14, 2015·The Lancet. Respiratory Medicine·Richard B MossUNKNOWN VX11-770-110 (KONDUCT) Study Group
Jul 2, 2015·American Journal of Respiratory and Critical Care Medicine·Gregory S SawickiMichael W Konstan
Apr 15, 2016·Annals of the American Thoracic Society·Emily A KnappBruce C Marshall
Jun 16, 2017·American Journal of Respiratory and Critical Care Medicine·Gregory S SawickiJeffrey S Wagener
Oct 19, 2017·International Journal of Epidemiology·David Taylor-RobinsonUNKNOWN CF-EpinNet collaboration

❮ Previous
Next ❯

Citations

Feb 2, 2019·Annals of the American Thoracic Society·Peter J Barry, Andrew M Jones
May 21, 2019·Pediatric Pulmonology·Adrienne P Savant, Susanna A McColley
Oct 19, 2019·Expert Review of Respiratory Medicine·Sarah L PatersonAlexander R Horsley
Jan 4, 2020·Acta Paediatrica·Kris De Boeck
Oct 28, 2019·The European Respiratory Journal·Vanessa MartelliAnne Louise Stephenson
Oct 30, 2019·Annals of the American Thoracic Society·Valentine SergeevBradley S Quon
Mar 11, 2020·Expert Review of Respiratory Medicine·Brianna C Aoyama, Peter J Mogayzel
Aug 4, 2020·Expert Opinion on Investigational Drugs·Ranjani SomayajiScott C Bell
Aug 11, 2020·Der Radiologe·Olaf Sommerburg, Jens-Peter Schenk
Aug 22, 2020·QJM : Monthly Journal of the Association of Physicians·Frost FNazareth D
Oct 24, 2018·Frontiers in Pharmacology·Pauline BardinOlivier Tabary
Jan 11, 2019·Der Internist·Patience Eschenhagen, Carsten Schwarz
Nov 8, 2019·The New England Journal of Medicine·Peter G MiddletonUNKNOWN VX17-445-102 Study Group
Mar 7, 2020·The European Respiratory Journal·Catherine RangTom Kotsimbos
Mar 11, 2020·Frontiers in Pharmacology·Miquéias Lopes-Pacheco
Jul 16, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Patricia McGettiganPeter G M Mol
Aug 23, 2020·International Journal of Molecular Sciences·Andrea GramegnaCarlo Castellani
Nov 22, 2020·Pediatric Pulmonology·Donatello SalvatoreGiuseppe Campagna
Dec 7, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kerstin BrinkertAntje Munder
Feb 16, 2021·Journal of Endocrinological Investigation·C ColomboA Battezzati
Feb 4, 2021·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Kathleen J RamosJennifer L Taylor-Cousar
Nov 30, 2020·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·J S GuimbellotUNKNOWN GOAL-e2 Investigators
Apr 4, 2021·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Christopher R KawalaAnne L Stephenson
Apr 8, 2021·Expert Opinion on Drug Discovery·Miquéias Lopes-PachecoGuido Veit
May 1, 2021·Journal of Clinical Medicine·Jamie DuckersFosca De Iorio
May 3, 2021·CPT: Pharmacometrics & Systems Pharmacology·Rachel A HodosPaul B McCray
Jun 23, 2020·Paediatric Respiratory Reviews·I M Balfour-Lynn, J A King
Jun 3, 2021·Journal of Personalized Medicine·Raksha Jain, Jennifer L Taylor-Cousar
Mar 19, 2021·American Journal of Respiratory and Critical Care Medicine·Edith T ZemanickSusanna A McColley
Apr 27, 2021·American Journal of Respiratory and Critical Care Medicine·Cori L Daines, Wayne J Morgan
Apr 5, 2021·Mycopathologia·Amelia BercussonAnand Shah
Aug 2, 2021·Orphanet Journal of Rare Diseases·Emily DiMangoCheng-Shiun Leu
Sep 11, 2019·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·D R VanDevanter, N Mayer-Hamblett
Aug 23, 2021·Current Opinion in Pulmonary Medicine·Peter J Barry, Jennifer L Taylor-Cousar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Respiratory and Critical Care Medicine
Jane C DaviesVX08-770-103 (ENVISION) Study Group
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Lucian FrenţescuGheorghe Benga
The New England Journal of Medicine
Mitchell L DrummGene Modifier Study Group
© 2022 Meta ULC. All rights reserved